PRINCETON, NJ--(Marketwire - February 12, 2008) - Ophthotech Corp. (“Ophthotech”), a privately held biopharmaceutical company focused on developing ophthalmic therapies for back-of-the-eye diseases, today announced that the first patient has been enrolled in its Phase I clinical trial for the treatment of wet age-related macular degeneration (AMD). The Phase I trial will assess the safety and tolerability of E10030, an anti-PDGF aptamer, in combination with an anti-VEGF agent. This trial will enroll up to a maximum of 36 patients.
